GU Oncology Now

Latest from Telix Pharmaceuticals Limited! The had approved the company’s lead imaging asset called Illuccix
Read about it here: https://www.docwirenews.com/gu-oncology-now/fda-approves-new-psma-pet-imaging-product-for-prostate-cancer/

FDA Approves New PSMA PET Imaging Product for Prostate Cancer Telix Pharmaceuticals today announces that the US Food and Drug Administration (FDA) has approved the company's lead prostate cancer imaging asset, called

Dr. Neeraj Agarwal discusses PSMA Imaging with Dr. Jonathan Tward, Dr. Scott Tagawa, and Dr. Jeremie Calais https://www.docwirenews.com/round-the-wire/what-is-psma-imaging-and-how-its-a-game-changer/

PSMA Imaging: What it is and how it’s a game changer In the first video of the roundtable series, Dr. Jeremie Calais reviews the basics of PSMA as a biological target for the PET imaging of prostate cancer.

On this Thanksgiving, we want to share our genuine appreciation for you. We wouldn’t be where we are today without you!

PSMA (prostate-specific membrane antigen) is over-expressed on the membrane of aggressive prostate cancer (PCa) cells, and as such has been found to be a promising target for the treatment of advanced PCa.

WordPress › Error

Prognostic value of lower urinary tract symptoms (LUTS) in with newly diagnosed regional lymph node-positive

Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-Positive Prostate Cancer A study explored the prognostic value of lower urinary tract symptoms (LUTS) in patients with newly diagnosed regional lymph node-positive prostate

Latest podcast from the ! Interview with Dr. Sam Gledhill

Episode 141: Movember - Past, Present and Future Sam Gledhill describes Movember and its work.   Tom: We're joined here today by Sam Gledhill from Movember. He's the... For digital health for the

PSMA-PET findings support risk groups based on the Prostate Cancer Guidelines Panel for biochemically recurrent (BCR)

PSMA PET Supports EAU Risk Groups for Biochemically Recurrent Prostate Cancer Prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) findings support risk groups based on the European Association of Urology

Physicians use precision medicine to discern people who might be at risk for cancer, identify cancer in its early stages, prevent some forms of cancer, choose the best treatment option.

Read more: https://www.docwirenews.com/gu-oncology-now/phenotypic-precision-medicine-gu-kh/the-benefits-of-precision-medicine-in-cancer/?utm_source=social&utm_medium=social&utm_campaign=social&utm_content=social

The Benefits of Precision Medicine in Cancer Precision medicine, often referred to as personalized medicine, is a form of medicine that utilizes information about an individual’s genes or proteins to

discussed novel therapies that are shaping the way advanced prostate cancer is treated.

Read more: https://www.docwirenews.com/condition-center/precision-medicine-in-prostate-cancer/precision-medicine-in-prostate-cancer-picks/dr-dan-george-duke-health-on-phenotypic-precision-medicine-in-prostate-cancer/?utm_source=social&utm_medium=social&utm_campaign=social&utm_content=social

Dr. Dan George, Duke Health, on Phenotypic Precision Medicine in Prostate Cancer GU Oncology Now recently spoke with Daniel Geroge, MD, a medical oncologist at Duke Cancer Center who specializes in genitourinary cancers. Dr. George

A preliminary study from assessed the link of circulating tumor cells (CTC) with inflammatory biomarkers in patients with metastatic castration-resistant prostate cancer (mCPRC).

Read more: https://www.docwirenews.com/gu-oncology-now/gu-oncology-now-picks/study-explores-link-between-ctc-count-and-inflammation-in-advanced-prostate-cancer/?utm_source=social&utm_medium=social&utm_campaign=social&utm_content=social

Study Explores Link between CTC Count and Inflammation in Advanced Prostate Cancer A preliminary study assessed the link of circulating tumor cells (CTC) with inflammatory biomarkers in patients with metastatic castration-resistant

Throw back! and discuss the accelerated approval.
https://www.docwirenews.com/gu-oncology-now/the-uromigos/uromigos-a-podcast/episode-96-odac-bladder-cancer-accelerated-approval-meeting/?utm_source=social&utm_medium=Social&utm_campaign=Social&utm_content=Social

Episode 96: ODAC - Bladder Cancer Accelerated Approval Meeting Andrea Apollo discusses highlights from the April 28th meeting.

NEW INTERVIEW! of discusses the development of new approaches to treating advanced
https://www.docwirenews.com/gu-oncology-now/phenotypic-precision-medicine-gu-kh/dr-andrew-armstrong-on-precision-medicine-approaches-in-advanced-prostate-cancer/?utm_source=social&utm_medium=Social&utm_campaign=Social&utm_content=Social

Dr. Andrew Armstrong on Precision Medicine Approaches in Advanced Prostate Cancer GU Oncology Now recently spoke with Andrew J. Armstrong, MD, a physician at Duke Cancer Institute Center for Prostate and Urologic Cancers. Dr. Armstrong

GU Oncology Now updated their business hours.

discussed novel therapies that are shaping the way advanced prostate cancer is treated.

Read more: https://www.docwirenews.com/condition-center/precision-medicine-in-prostate-cancer/precision-medicine-in-prostate-cancer-picks/dr-dan-george-duke-health-on-phenotypic-precision-medicine-in-prostate-cancer/?utm_source=social&utm_medium=social&utm_campaign=social&utm_content=social

Dr. Dan George, Duke Health, on Phenotypic Precision Medicine in Prostate Cancer GU Oncology Now recently spoke with Daniel Geroge, MD, a medical oncologist at Duke Cancer Center who specializes in genitourinary cancers. Dr. George

Researchers constructed an effective signature to predict the prognosis of prostate cancer (PCa) and identify the biofunctions of signature-related genes.

Read more: https://www.docwirenews.com/gu-oncology-now/gu-oncology-now-picks/a-prognostic-signature-for-treatment-planning-and-evaluation-in-prostate-cancer/?utm_source=social&utm_medium=social&utm_campaign=social&utm_content=social

A Prognostic Signature for Treatment Planning and Evaluation in Prostate Cancer Researchers constructed an effective signature to predict the prognosis of prostate cancer (PCa) and identify the biofunctions of signature-related genes.

The findings of a study indicate that bone mineral testing should be performed for prostate cancer patients undergoing androgen deprivation therapy (ADT) as osteoporosis is common in this population.

Read more: https://www.docwirenews.com/gu-oncology-now/gu-oncology-now-picks/bone-mineral-density-testing-is-important-in-non-metastatic-prostate-cancer-patients-undergoing-adt/?utm_source=social&utm_medium=social&utm_campaign=social&utm_content=social

Bone Mineral Density Testing Is Important in Non-Metastatic Prostate Cancer Patients Undergoing ADT The findings of a study indicate that bone mineral testing should be performed for prostate cancer patients undergoing androgen deprivation therapy (ADT)